TScan Therapeutics (TCRX)
Develops TCR-engineered T-cell therapies for cancer through a T-cell receptor discovery platform.
Something off on this page? Send us feedback.
A clinical-stage biopharmaceutical company developing TCR-engineered T-cell therapies for cancer. It applies a T-cell receptor discovery platform to build a TCR-T pipeline rather than relying on an already marketed drug.
Develops T-cell receptor-engineered T-cell therapies for cancer as a clinical-stage biopharmaceutical company. Its TargetScan discovery technology is intended to reveal how T cells naturally recognize cancer and inform a pipeline of TCR-T candidates.
Founded in 2018 and headquartered in Waltham, Massachusetts, the company takes a platform-built approach rather than operating around an already marketed drug. Its progress depends on advancing TCR-T candidates and its discovery platform into therapies for cancer.
The company has also worked with Novartis to discover and develop TCR-engineered therapies for solid tumors, while retaining the ability to develop targets that Novartis does not license.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 8, 2026 | H.C. Wainwright | Downgrade | Target: — | Target: $1 |
| Sep 8, 2026 | HC Wainwright & Co. | Downgrade | ||
| Sep 3, 2026 | Wedbush | Downgrade | ||
| Sep 2, 2026 | Needham | Downgrade | ||
| Sep 2, 2026 | Wedbush | Downgrade | Target: — | Target: $1 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $100.2M · Total debt $90.9M · Total assets $171.5M · Shareholders' equity $69.0M
- Revenue
- $1.1M
- Operating income
- −$30.5M
- Net income
- −$30.4M
No dividends on record.
| Institutions | 105.74% | 71.67M shares | |
|---|---|---|---|
| 59 holders · as of Jun 30, 2026 | |||
| Insiders | 0.07% | 45.0K shares | |
| 1 holder · as of Sep 24, 2024 | |||
| Strategic holders | 5.32% | 3.60M shares | |
| 1 holder · as of Feb 14, 2025 | |||
| Adds to | 111.13% | ||
67.78M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (67.78M in the company's Sep 23, 2026 report, 61.07M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 111.13%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Lynx1 Capital Management LPInstitution | 23.66% | 8.02M · 8.02M | as of Jun 30, 2026 |
BVF Inc/ILInstitution | 16.42% | 5.56M · 5.56M | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 8.22% | 2.78M · 2.78M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.37% | 2.16M · 2.16M | as of Jun 30, 2026 |
Two Sigma Investments, LPInstitution | 5.75% | 1.95M · 1.95M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 19, 2025 | Lynx1 Capital Management LP | 10 percent owner | +80,069 | $0.8989 |
| Dec 22, 2025 | Lynx1 Capital Management LP | 10 percent owner | +75,500 | $0.9000 |
| Dec 23, 2025 | Lynx1 Capital Management LP | 10 percent owner | +6,232 | $0.8989 |
- Immatics
Clinical TCR-T and TCR-bispecific programs for cancer
- Immunocore (ADR)
TCR-bispecific cancer medicines and HLA-restricted targets
- Iovance Biotherapeutics
Commercial and investigational tumor-infiltrating lymphocyte therapies
- Gilead Sciences
Kite cell therapies for aggressive blood cancers
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| TScan Therapeutics | $0.3537 | −0.31% | $21.7M | — | — | 3.0 | −65.8% |
| Immatics | $8.64 | −2.59% | $1.19B | — | — | 25.0 | +113.0% |
| Immunocore (ADR) | $31.13 | −3.98% | $1.65B | — | — | 4.1 | −13.7% |
| Iovance Biotherapeutics | $10.23 | −3.90% | $4.75B | — | — | 14.6 | +65.7% |
| Gilead Sciences | $150.95 | −1.13% | $189.30B | — | 16.7 | 6.2 | +10.2% |
| Median | — | 16.7 | 10.4 | +37.9% |